SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Decline in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 39,900 shares, a decrease of 32.1% from the October 31st total of 58,800 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 74,700 shares, the short-interest ratio is presently 0.5 days.

SAB Biotherapeutics Trading Up 0.7 %

Shares of SAB Biotherapeutics stock traded up $0.02 during trading on Friday, hitting $2.97. 49,774 shares of the stock were exchanged, compared to its average volume of 31,948. The stock’s fifty day moving average is $3.00 and its 200 day moving average is $2.92. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 12 month low of $2.16 and a 12 month high of $9.72.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. On average, research analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

SABS has been the topic of several research reports. Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Oppenheimer reissued an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Finally, Craig Hallum initiated coverage on SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, SAB Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $12.40.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC acquired a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics at the end of the most recent quarter. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.